Rhythm Pharmaceuticals
Logotype for Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals (RYTM) investor relations material

Rhythm Pharmaceuticals Stifel 2026 Healthcare Conference 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Rhythm Pharmaceuticals Inc
Stifel 2026 Healthcare Conference 2026 summary11 Nov, 2026

U.S. AHO launch

  • More than 700 start forms and ~500 unique HCP prescribers reported after approval in March; 25% of HCPs were repeat prescribers.

  • Excluding clinical trial patients, the Q2 pace continued through October; management expects the pace to continue, supported by broad reach across targeted endocrinologists.

  • Endocrinology capacity and patients’ regularly scheduled visits for hormone replacement can limit how quickly diagnosed patients move to treatment.

  • Payer adoption of positive coverage policies has been faster than for BBS, supported by existing drug availability, stronger data and the severity of the underlying injury.

  • Through 2027, priorities include broadening patients on therapy, increasing HCP reach and repeat prescribing, and supporting continued revenue growth.

Japan and other ex-U.S. markets

  • AHO was approved in Japan in October; more than 1,000 patients have been identified and treatment has begun.

  • First-year Japanese uptake is expected to be modest because prescriptions must be renewed every two weeks for the first 12 months; management expects launch momentum to build after the restriction lifts.

  • Japan AHO prevalence is estimated at 5,000–8,000 patients, versus ~10,000 in the U.S.; management cited higher craniopharyngioma incidence, expected higher diagnosis and supportive market conditions.

  • Germany reimbursement exception is expected in Q1, followed by launch; France launch is anticipated in 2027 after supplemental price negotiation, while Italy and U.K. access efforts are also progressing.

  • Management expects a higher ex-U.S. AHO contribution in 2027 as launches take hold, with more specific timelines to come early in the year.

Bivamelagon and Prader-Willi syndrome

  • A licensing amendment commits $350 million over four years to reduce bivamelagon royalties from 5%–7% to 1%, removing an economic disincentive to development.

  • Bivamelagon is planned to lead next-generation PWS development; management hopes to meet the FDA in 2027 and start a hyperphagia-focused study that year.

  • The proposed PWS Phase III study is six months, placebo-controlled, with HQ-CT as the primary endpoint; clinically meaningful hyperphagia measured by HQ-CT is expected to be an entry criterion.

  • In Phase II, all six adults with clinically meaningful hyperphagia had HQ-CT reductions through six months, as did three of five children; management expects placebo effects to normalize by six months.

  • Bivamelagon was selected ahead of RM-718 based on clinical supply readiness, KOL feedback favoring daily routine administration, and the revised royalty economics.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Rhythm Pharmaceuticals earnings date

Logotype for Rhythm Pharmaceuticals Inc
Q4 202625 Feb, 2027
Rhythm Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Rhythm Pharmaceuticals earnings date

Logotype for Rhythm Pharmaceuticals Inc
Q4 202625 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Rhythm Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for rare genetic disorders related to obesity. The company’s primary area of focus is on conditions caused by impairments in the melanocortin-4 receptor (MC4R) pathway, which regulates hunger and body weight. Rhythm Pharmaceuticals aims to address unmet medical needs by developing targeted therapies that can help manage severe obesity and related symptoms in patients with specific genetic deficiencies. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.